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1. INTRODUCTION {#jmv25397-sec-0050}
===============

Kidney transplant (KTx) recipients are at high risk of developing viral infections due to the immunosuppressive treatment required to prevent allograft rejection. BK polyomavirus (BKPyV) infection poses a threat to the transplanted kidney. Primary BKPyV infection occurs early in life and causes persistent (life‐long) asymptomatic infection, rendering \~90% of adults seropositive.[1](#jmv25397-bib-0001){ref-type="ref"}, [2](#jmv25397-bib-0002){ref-type="ref"} Thereafter, the virus resides in urothelium and renal tubular cells.[3](#jmv25397-bib-0003){ref-type="ref"}, [4](#jmv25397-bib-0004){ref-type="ref"} Reactivation of BKPyV occurs in immunocompromised patients indicated by the presence of viral DNA in urine (viruria) and blood (viremia), manifesting itself as hemorrhagic cystitis and BKPyV‐associated nephropathy (BKPyVAN). BKPyVAN of the renal allograft is seen in 1% to 10% of KTx recipients and ultimately causes allograft failure, unless immunosuppression is tapered.[5](#jmv25397-bib-0005){ref-type="ref"}, [6](#jmv25397-bib-0006){ref-type="ref"}, [7](#jmv25397-bib-0007){ref-type="ref"} Recently we found BKPyV‐specific immunoglobulin G (IgG) levels, especially determined in donors before KTx, to be strongly predictive of BKPyV viremia and BKPyVAN in recipients after KTx.[5](#jmv25397-bib-0005){ref-type="ref"}

BKPyV is a member of the Polyomaviridae, which among others contains 13 species detected in humans,[8](#jmv25397-bib-0008){ref-type="ref"} including human polyomavirus 9 (HPyV9) and trichodysplasia spinulosa polyomavirus (TSPyV). TSPyV primary infection causes trichodysplasia spinulosa in immunocompromised patients, in whom it can be found in large quantities in affected skin and blood, but also in kidney tissue and urine.[9](#jmv25397-bib-0009){ref-type="ref"}, [10](#jmv25397-bib-0010){ref-type="ref"}, [11](#jmv25397-bib-0011){ref-type="ref"}, [12](#jmv25397-bib-0012){ref-type="ref"}, [13](#jmv25397-bib-0013){ref-type="ref"} TSPyV seroprevalence in healthy populations is high, approximately 75%,[1](#jmv25397-bib-0001){ref-type="ref"}, [14](#jmv25397-bib-0014){ref-type="ref"} which suggests that asymptomatic persistent TSPyV infection is common.

HPyV9 was discovered in serum of a KTx patient.[15](#jmv25397-bib-0015){ref-type="ref"} A role for HPyV9 in hemorrhagic cystitis, bladder cancer, cutaneous T‐cell lymphoma, and cutaneous squamous cell carcinoma has been explored, but thus far no pathogenic effect of HPyV9 has been found. Seroprevalence for this virus is lower than most other HPyVs (\~20%).[1](#jmv25397-bib-0001){ref-type="ref"}, [14](#jmv25397-bib-0014){ref-type="ref"}, [16](#jmv25397-bib-0016){ref-type="ref"}

We have previously observed an association between the HPyV9 and BKPyV infection in a small cohort of, mostly cadaveric, kidney(‐pancreas) transplant patients (n = 99). Approximately 20% of these patients became HPyV9 viremic after KTx, which preferentially occurred among BKPyV viremic recipients (*P* \< 0.05), especially in those with high BKPyV DNA loads (\>10^3^ copies/mL).[17](#jmv25397-bib-0017){ref-type="ref"} An association with *Cytomegalovirus* (CMV) viremia was not found, suggesting that the association between the HPyV9 and BKPyV was not merely the result of increased immunosuppression, but rather of a common risk factor shared between these polyomaviruses.

Since the detection of HPyV9 was associated with higher BKPyV loads, we wondered if HPyV9 somehow promotes BKPyV infection and could be involved in BKPyVAN development in KTx patients. In this study, we tested this hypothesis, although we are not aware of any documented complementarity/synergy between polyomaviruses, as for instance has been described between DNA viruses, such as hepatitis B and D virus.[18](#jmv25397-bib-0018){ref-type="ref"} At the same time, this approach offered the possibility to confirm our previously reported HPyV9 viremia rates in KTx patients, which were not found in a number of other comparable studies.[15](#jmv25397-bib-0015){ref-type="ref"}, [19](#jmv25397-bib-0019){ref-type="ref"} Since TSPyV belongs to the same genus as HPyV9 (alpha polyomavirus), and is also detected in kidney tissue and urine, we included this polyomavirus in the analysis as well.

2. OBJECTIVE {#jmv25397-sec-0060}
============

The aim of this study was to investigate the association between the HPyV9 and TSPyV coinfection and the development of BKPyV viremia and BKPyVAN in KTx recipients.

3. MATERIALS AND METHODS {#jmv25397-sec-0070}
========================

3.1. Study population and sample collection {#jmv25397-sec-0080}
-------------------------------------------

The current study cohort was part of an established group of 407 KTx living adult (age \> 18) donor‐recipient pairs transplanted at the Leiden University Medical Center between 2003 and 2012.[5](#jmv25397-bib-0005){ref-type="ref"} Recipients for which no baseline or less than two plasma samples were available, or have been transplanted twice with different donors, were excluded from this cohort. All other recipients have been included. HPyV9 and TSPyV serology and polymerase chain reaction (PCR) was performed on the 209 donor‐recipient pairs with the oldest KTx dates, from 2003 to 2011. Blood samples for BKPyV DNA screening were collected as part of routine virus screening, before transplantation, and 1.5, 3, 6, 9, and 12 months after transplantation, with a median of 3.6‐time points analyzed per recipient. Wunderink et al[5](#jmv25397-bib-0005){ref-type="ref"} reported a detailed description of study design and population, data collection, and medical ethical approval.

3.2. Seroresponsedetection of BKPyV, HPyV9, and TSPyV {#jmv25397-sec-0090}
-----------------------------------------------------

An in‐house Luminex immunoassay (Austin, TX) detecting IgG reactivity against major viral protein 1 of BKPyV, HPyV9, and TSPyV expressed as median fluorescence intensity (MFI) was performed on serum and plasma samples of donors and recipients, as described.[5](#jmv25397-bib-0005){ref-type="ref"}, [20](#jmv25397-bib-0020){ref-type="ref"}

3.3. DNA detection of BKPyV, TSPyV, and HPyV9 {#jmv25397-sec-0100}
---------------------------------------------

BKPyV, HPyV9, and TSPyV viremia was determined in serum and plasma with quantitative real‐time PCR, as described.[5](#jmv25397-bib-0005){ref-type="ref"}, [10](#jmv25397-bib-0010){ref-type="ref"}, [17](#jmv25397-bib-0017){ref-type="ref"}

3.4. Assessment of BKPyVAN development {#jmv25397-sec-0110}
--------------------------------------

BKPyVAN was determined by kidney biopsy, performed if clinically indicated according to the treating physician. The biopsy specimen was stained for BKPyV large T antigen with mouse monoclonal antibody PAb416 (Calbiochem; EMD Millipore, Billerica, MA) raised against large T antigen of SV40 polyomavirus.

3.5. Statistical analyses {#jmv25397-sec-0120}
-------------------------

Data were analyzed with IBM SPSS Statistics for Windows, Version 23.0 (IBM Corp, Armonk, NY). Descriptive analyses were used to report cohort characteristics, the comparison of the baseline characteristics and the association between the HPyV9 and TSPyV. The outcome variables were assessed using the χ^2^ test, the Fisher exact test, or the Student *t* test, as appropriate. Logistic regression was used to test whether donor and recipient HPyV9 or TSPyV seropositivity statistically modified the predictive effect of the BKPyV donor seroreactivity level on the development of BKPyV viremia. Tests were considered statistically significant with *P* \< 0.05 in a two‐sided test.

4. RESULTS {#jmv25397-sec-0130}
==========

4.1. Incidence of BKPyV viremia and BKPyVAN {#jmv25397-sec-0140}
-------------------------------------------

In total, 209 KTx recipients were evaluated with regard to the incidence of BKPyV viremia and BKPyVAN within the first year after KTx. Fifty‐three recipients (25%) became BKPyV viremic, and four of them developed BKPyVAN (Table [1](#jmv25397-tbl-0001){ref-type="table"}).

###### 

Basic and donor characteristics of KTx recipients sorted for the development of BKPyV viremia and BKPyVAN during the first year after transplantation

                              All recipients (n = 209)   Viremic recipients(n = 53)                                  
  --------------------------- -------------------------- ---------------------------- ------- ----------- ---------- -------
  Recipient age, n (SD)       49 (13.0)                  53 (14.1)                    0.113   52 (14.5)   58 (5.8)   0.131
  Recipient male sex, n (%)   96 (62)                    39 (74)                      0.113   36 (74)     3 (75)     1.000
  Donor age, n (SD)           51 (10.8)                  55 (11.3)                    0.028   55 (11.3)   63 (8.6)   0.160
  Donor male sex, n (%)       57 (37)                    21 (40)                      0.688   18 (37)     3 (75)     0.132

Abbreviations: BKPyV, BK polyomavirus; BKPyVAN, BKPyV‐associated nephropathy; KTx, kidney transplantation; SD, standard deviation.

John Wiley & Sons, Ltd.

4.2. HPyV9 and TSPyV seropositivity and viremia among KTx donors and recipients {#jmv25397-sec-0150}
-------------------------------------------------------------------------------

To investigate a possible effect on BKPyV infection and development of BKPyV viremia and BKPyVAN by coinfection with HPyV9 and TSPyV, pre‐KTx seropositivity for HPyV9 and TSPyV were determined in both donors and recipients. Forty‐five donors (22%) and 33 recipients (16%) were seropositive for HPyV9, and 184 donors (88%) and 186 recipients (89%) for TSPyV (Figure [1](#jmv25397-fig-0001){ref-type="fig"}). HPyV9 and TSPyV seropositivity were distributed equally over age and sex of recipients (Table [2](#jmv25397-tbl-0002){ref-type="table"}) and donors (not shown). When comparing HPyV9 and TSPyV seropositivity among donors and their corresponding recipients, associations were noticed between donor and recipient HPyV9 serostatus (*P* \< 0.001), as well as TSPyV serostatus (*P* = 0.27) (Table [2](#jmv25397-tbl-0002){ref-type="table"}). None of the recipients\' developed HPyV9 viremia post‐KTx, while two developed TSPyV viremias.

![Pre‐KTx, HPyV9, and TSPyV seropositivity and seroreactivity of donors and recipients. HPyV9, human polyomavirus 9; KTx, kidney transplantation; MFI, median fluorescence intensity; TSPyV, trichodysplasia spinulosa polyomavirus](JMV-91-1142-g001){#jmv25397-fig-0001}

###### 

Distribution of TSPyV and HPyV9 seropositivity among 209 KTx recipients related to age, sex, and donor TSPyV and HPyV9 seropositivity

                                      Recipient HPyV9 serostatus   Recipient TSPyV serostatus                                     
  ----------------------------------- ---------------------------- ---------------------------- --------- ----------- ----------- -------
  Age, n (SD)                         51 (13.5)                    48 (12.6)                    0.379     50 (12.0)   50 (13.5)   0.810
  Male sex, n (%)                     112 (64)                     23 (70)                      0.504     12 (52)     123 (66)    0.247
  Donor HPyV9 seropositivity, n (%)   29 (17)                      16 (48)                      \<0.000   8 (35)      37 (20)     0.101
  Donor TSPyV seropositivity, n (%)   154 (88)                     30 (91)                      0.580     17 (74)     167 (90)    0.027

Abbreviations: HPyV9, human polyomavirus 9; KTx, kidney transplantation; SD, standard deviation; TSPyV, trichodysplasia spinulosa polyomavirus.

John Wiley & Sons, Ltd.

4.3. Association between HPyV9 and TSPyV serostatus and development of BKPyV viremia and BKPyVAN {#jmv25397-sec-0160}
------------------------------------------------------------------------------------------------

To investigate the association between TSPyV and HPyV9 serostatus and development of BKPyV infection and BKPyVAN in the first year after KTx, HPyV9 and TSPyV pre‐KTx seropositivity and seroreactivity (MFI value) of both donors and recipients were compared with the development of BKPyV viremia and BKPyVAN in recipients (Table [3](#jmv25397-tbl-0003){ref-type="table"}). HPyV9 nor TSPyV serostatus was associated with the development of BKPyV viremia and BKPyVAN. For HPyV9, a positive association was found between pre‐KTx recipient seroreactivity and development of BKPyVAN within one year after transplantation (*P* = 0.007). This was not observed for BKPyV viremia. Donor nor recipient TSPyV seroreactivity was associated with the development of BKPyV viremia and BKPyVAN.

###### 

Pre‐KTx seropositivity and seroreactivity of donors and recipients sorted for BKPyV viremia and BKPyVAN during the first year after transplantation, shown for HPyV9 and TSPyV

                                             All recipients(n = 209)   Viremic recipients(n = 53)                                        
  ------------------------------------------ ------------------------- ---------------------------- ------- ------------- -------------- -------
  HPyV9                                                                                                                                  
  Donor seropositivity, n (%)                36 (23)                   9 (17)                       0.351   40 (82)       4 (100)        1.000
  Donor seroreactivity, MFI value (SD)       1458 (4769)               1045 (4189)                  0.575   1123 (4350)   90 (348)       0.640
  Recipient seropositivity, n (%)            28 (18)                   5 (9)                        0.142   4 (8)         1 (25)         0.336
  Recipient seroreactivity, MFI value (SD)   1627 (5315)               632 (3747)                   0.208   245 (2526)    5371 (10432)   0.007
  TSPyV                                                                                                                                  
  Donor seropositivity, n (%)                138 (86)                  46 (87)                      0.746   42 (86)       4 (100)        1.000
  Donor seroreactivity, MFI value (SD)       9384 (6396)               8399 (5569)                  0.287   8601 (5676)   5921 (3623)    0.243
  Recipient seropositivity, n (%)            141 (90)                  45 (85)                      0.271   41 (84)       4 (100)        1.000
  Recipient seroreactivity, MFI value (SD)   8959 (5868)               8321 (6083)                  0.507   8311 (6179)   8446 (5523)    0.965

Abbreviations: BKPyV, BK polyomavirus; BKPyVAN, BKPyV‐associated nephropathy; MFI, median fluorescence intensity; SD, standard deviation.

John Wiley & Sons, Ltd.

The strong association between pre‐KTx donor BKPyV seroreactivity and recipient BKPyV viremia and BKPyVAN, reported previously,[5](#jmv25397-bib-0005){ref-type="ref"} was not influenced by the donor or recipient pre‐KTx HPyV9 or TSPyV serostatus or seroreactivity (data not shown).

5. DISCUSSION {#jmv25397-sec-0170}
=============

Prompted by an increased BK viremia rate previously observed among HPyV9‐infected KTx recipients, we investigated whether HPyV coinfection, especially with HPyV9 and TSPyV is of influence to the development of BKPyV viremia and BKPyVAN in KTx recipients. Therefore, we determined the HPyV9 and TSPyV seroresponses in donor and recipient serum samples collected before KTx and detected the presence of HPyV9 and TSPyV DNA in blood plasma samples of KTx recipients collected within one year after KTx.

HPyV9 and TSPyV seroreactivity was comparable between donors and recipients, and showed the same distribution pattern as known from other immunocompetent and immunosuppressed populations: a high overall number of TSPyV seropositives, and approximately 20% seropositivity for HPyV9.[2](#jmv25397-bib-0002){ref-type="ref"}, [20](#jmv25397-bib-0020){ref-type="ref"} In comparing HPyV9 and TSPyV seroresponses among donors and recipients, we observed statistically significant associations between donor and recipient seropositivity for both viruses. Since the analyzed cohort consists of living donors, a considerable part of the donors and recipients is related as parent‐child or as siblings and might have had similar virus exposure at a younger age while sharing the same household. Indeed, Pedergnana et al[21](#jmv25397-bib-0021){ref-type="ref"} found indication for TSPyV transmission from parents to children, and between siblings. Currently the mechanism for transmission of HPyV9 remains unidentified; however, Karachaliou et al[22](#jmv25397-bib-0022){ref-type="ref"} identified younger age at day‐care entry as risk factor.[23](#jmv25397-bib-0023){ref-type="ref"} Alternatively, household/family members might share genetic risk factors and glycan receptors relevant for these viruses, for example, the acquisition of the HPyV9 glycan receptor ligand, which Khan et al[24](#jmv25397-bib-0024){ref-type="ref"} speculated to be acquired through the consumption of red meat and milk. Although we were informed about the (familial) relation between donor and recipient (sibling, parent, other families, partner, friends, or strangers), no trend towards a relationship with increased risk of HPyV9 infection was found (data not shown).

When we compared the incidence of BKPyV viremia and BKPyVAN in HPyV9 and TSPyV seropositive recipients, we did not observe specific associations to suggest that the BKPyV infection was related to previous or coincident HPyV9 or TSPyV infection. Only the MFI values for HPyV9 were significantly higher in BKPyV viremic recipients that developed BKPyVAN (*P* = 0.007). However, because this concerned only four recipients developing nephropathy, we are reluctant to conclude anything from this observation.

Previously we reported 21% HPyV9 DNA‐positive KTx recipients in a cohort of kidney‐pancreas transplant patients with deceased donors.[17](#jmv25397-bib-0017){ref-type="ref"} This percentage is much higher than the prevalence found in this study where none of the recipients turned HPyV9 DNA‐positive. This discrepancy might be explained by a number of things. First, the cohort of the previous study contained primarily deceased donors, which conceivably could have a different health status than healthy living donors. Second, a substantial amount of the recipients in the previous cohort received kidney‐pancreas transplantation, which has been shown to have a higher chance of developing late‐onset BKPyVAN.[25](#jmv25397-bib-0025){ref-type="ref"} Furthermore, the overrepresentation of diabetes mellitus type I patients in the kidney‐pancreas transplant cohort might have introduced additional, unknown risk factors for HPyV9 infection.

The 0.5% prevalence of TSPyV viremia that we observed in the KTx patients cohort reported here is lower than previously found by Urbano et al,[26](#jmv25397-bib-0026){ref-type="ref"} who reported a prevalence of 27% in the KTx patients.[27](#jmv25397-bib-0027){ref-type="ref"} We assume that different immunosuppressive regimens or geographical differences explain the discrepancy in the prevalence of TSPyV infection in the primarily Dutch and Argentinian cohorts.

Recent data from our lab published by Wunderink et al[5](#jmv25397-bib-0005){ref-type="ref"} suggest that the BKPyV infection post‐KTx originates from the donor and that the level of donor BKPyV IgG seroreactivity can be used to predict the development of BKPyV viremia and BKPyVAN in the recipient. Our current data showed that the donor and recipient HPyV9 and TSPyV seroreactivity do not modify the predictive effect of donor BKPyV seroreactivity on the development of BKPyV infection in the recipient.

In summary, in this cohort of living KTx donor‐recipient pairs, we did not find evidence for relevant HPyV9 and TSPyV infections occurring in immunosuppressed recipients after KTx. Furthermore, we did not find an association between the HPyV9 or TSPyV infection and the development of BKPyV viremia and BKPyVAN, and also no modifying effect of HPyV9 or TSPyV serostatus or seroreactivity on the prediction of BKPyV viremia and BKPyVAN based on pre‐KTx donor BKPyV seroreactivity. Altogether, we did not find indication for complementarity or synergy between the HPyV9, TSPyV, and BKPyV infection. Therefore, further study into the role of HPyV9 and TSPyV in the development of BKPyVAN does not seem warranted.
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